cerca CERCA
Venerdì 26 Aprile 2024
Aggiornato: 10:56
10 ultim'ora BREAKING NEWS

Comunicato stampa

ShanghaiTech Scientists Resolve the Structure of the Human "Marijuana Receptor"

20 ottobre 2016 | 18.00
LETTURA: 2 minuti

SHANGHAI, Oct. 20, 2016 /PRNewswire/ -- A team of scientists led by the iHuman Institute of ShanghaiTech University has determined and analyzed the high-resolution atomic structure of human cannabinoid receptor 1 (CB1), also known as the "marijuana receptor". The three dimensional image of CB1 presented October 20th in Cell, could explain how pain medications meant to mimic cannabis use without the "high" can cause unintended side effects, and provide a foundation for future therapies.

"The detailed molecular structure of the receptor in complex with agonist or antagonist will help people understand how cellular signaling is affected by medicine molecules, and will offer a valuable framework for designing safer and more effective drugs", said iHuman Deputy Director and Professor Zhi-Jie Liu, one of the corresponding authors of the paper.

The 3D images reveal how molecules like THC bind to CB1, which is found embedded in the surface of many nerve cells. "Researchers are fascinated by how you can make changes in THC or synthetic cannabinoids and have such different effects," says iHuman Founding Director and Professor Raymond Stevens, co-leader of the study, "Now that we finally have the structure of CB1, we can start to understand how these changes to the drug structure can affect the receptor."

The first author of this study, Tian Hua, a graduate student at Prof. Zhi-Jie Liu's lab, and her colleagues determined the crystal structure of CB1 in complex with AM6538 at 2.8 Å resolution. AM6538, synthesized by the second author Kiran Vemuri from Northeastern University, USA, is expected to have a long half-life and be potentially useful in the treatment of addiction disorders. Additionally, their studies found a number of structurally dissimilar CB1 ligands can be accommodated when docked into the binding domain defined by the CB1 crystal structure. This should allow a diverse set of CB1 ligands to interact with CB1 through different binding motifs and have distinct pharmacological profiles.

Author Contact:

Zhi-Jie Liu, PhDProfessor, iHuman InstituteShanghaiTech Universityliuzhj@shanghaitech.edu.cn

Media Contacts:

Xun Liu, PhDPress Officer, ShanghaiTech Universityliuxun@shanghaitech.edu.cnPhone: +86-21-2068-5159

Photo - http://photos.prnewswire.com/prnh/20161019/430264Photo - http://photos.prnewswire.com/prnh/20161019/430265

Riproduzione riservata
© Copyright Adnkronos
Tag
Vedi anche


SEGUICI SUI SOCIAL



threads whatsapp linkedin twitter youtube facebook instagram
ora in
Prima pagina
articoli
in Evidenza